Method for producing a condensed adhesive phase of silk fusion proteins

Abstract

The present invention is directed to a method for producing a condensed phase of a silk fusion protein, the method comprising the steps of preparing a solution of a silk fusion protein in an aqueous medium and concentrating the silk fusion protein in the aqueous medium, wherein the fusion protein is isolated from a recombinant production host and comprises a silk-like protein sequence and two separate non-silk terminal module sequences, such as cellulose binding modules, SpyCatcher domains, tenth type III module of Fibronectin, gamma-crystallin D, flanking the silk-like protein sequence; wherein the method is performed so that the silk fusion protein is not precipitated and subsequently dissolved to the aqueous medium. The present invention is also directed to using such fusion proteins as adhesives.

Claims

1. A method for producing a condensed phase of a silk fusion protein, the method comprising the steps of: a) preparing a solution of a silk fusion protein in an aqueous medium, wherein said silk fusion protein is isolated from a recombinant production host and comprises a silk-like protein sequence and two separate non-silk terminal module sequences flanking said silk-like protein sequence; b) concentrating said silk fusion protein in said aqueous medium until a liquid phase separation occurs at about 1% w/v; c) collecting a protein containing phase of said aqueous medium obtained in step (b); d) repeating steps (b) and (c) with the protein containing phase obtained in step (c) until a protein concentration of about 20-45% w/v is reached; e) optionally separating aggregates of the silk fusion protein from soluble fusion proteins obtained in step (d) and removing the aggregates from the protein containing phase; and f) concentrating the protein containing phase obtained in step (d) or (e) to form a concentrate with a final protein concentration of about 60-80% w/v, wherein the steps (a) to (f) are performed so that said silk fusion protein is not precipitated and subsequently dissolved in said aqueous medium.

2. The method according to claim 1, wherein the method further comprises: (g) preparing silk fusion protein fibers from the concentrate obtained from step (f).

3. The method according to claim 1, wherein steps (b) and (f) are performed by centrifugal force and/or evaporation.

4. The method according to claim 1, wherein said aqueous medium is water or an aqueous buffer.

5. The method according to claim 1, wherein said silk fusion protein comprises a spider silk protein repeat sequence.

6. The method according to claim 5, wherein said spider silk protein repeat sequence comprises 10-50 spider silk polymer repeats, and wherein the repeat sequence comprises repeat A sequence of SEQ ID NO: 1 or a variant thereof combined with repeat Q sequence of SEQ ID NO: 2 or a variant thereof.

7. The method according to claim 6, wherein said spider silk protein repeat sequence is (AQ)12.

8. The method according to claim 5, wherein said spider silk protein repeat sequence is Araneus diadematus ADF3 comprising the sequence of SEQ ID NO:3, the Latrodectus hesperus AcSp1 sequence of SEQ ID NO:4 or a variant thereof.

9. The method according to claim 1, wherein said non-silk terminal module sequences flanking said silk-like protein sequence comprise cellulose binding modules (CBMs), SpyCatcher domains, gamma-crystallin D domains, tenth type III modules of fibronectin or a mixed pair thereof.

10. The method according to claim 9, wherein said cellulose binding module (CBM) is from Clostridium thermocellum comprising the sequence of SEQ ID NO:7 or a variant thereof, and said SpyCatcher domain is an engineered variant of fibronectin-binding protein FbaB of Streptococcus pyogenes comprising the sequence of SEQ ID NO:14 or a variant thereof.

11. The method according to claim 9, wherein said cellulose binding modules or said SpyCatcher domains flanking said silk-like protein sequence are linked to said silk-like protein sequence by a linker sequence, and wherein said linker sequence is selected from the group consisting of: a C-terminal linker of SEQ ID NO:6 and a N-terminal linker of SEQ ID NO:5.

12. The method according to claim 2, wherein the fibers are prepared in step g) by pulling the fibers from the concentrate by a pulling force.

13. The method according to claim 1, wherein said non-silk terminal module sequences comprise consecutive β-strands forming a β-sheet, and wherein a length of said non-silk terminal module sequences are in a range of 90-250 amino acids.

14. The method according to claim 1, wherein said non-silk terminal module sequences comprise a pair or a mixed pair of peptides flanking said silk-like protein sequence, wherein said peptides are selected from the group consisting of: cellulose binding module (CBM), SpyCatcher domain, tenth type III module of Fibronectin, gamma-crystallin D, green fluorescence protein (GFP), enhanced green fluorescence protein (EGFP), ubiquitin-like protein SMT3, thioredoxin 1, SnoopCatcher domain, cohesin, R2 protein, tumor necrosis factor cytokine CD40 ligand, tumor necrosis factor, B-cell activating factor (BAFF) and variants or homologs thereof.

15. A method for producing a condensed phase of a silk fusion protein, the method comprising the steps of: a) preparing a solution of a silk fusion protein in an aqueous medium, wherein said silk fusion protein is isolated from a recombinant production host and comprises a silk-like protein sequence and two separate non-silk terminal module sequences flanking said silk-like protein sequence; b) concentrating said silk fusion protein in said aqueous medium until a liquid phase separation occurs at about 1% w/v; c) collecting a protein containing phase of said aqueous medium obtained in step (b); d) repeating steps (b) and (c) with the protein containing phase obtained in step (c) until a protein concentration of about 20-45% w/v is reached; e) optionally separating aggregates of the silk fusion protein from soluble fusion proteins obtained in step (d) and removing the aggregates from the protein containing phase; and f) concentrating the protein containing phase obtained in step (d) or (e) to form a concentrate with a final protein concentration of about 60-80% w/v, wherein the steps (a) to (f) are performed so that said silk fusion protein is not precipitated and subsequently dissolved in said aqueous medium, wherein said non-silk terminal module sequences flanking said silk-like protein sequence comprise cellulose binding modules (CBMs), SpyCatcher domains, gamma-crystallin D domains, tenth type III modules of fibronectin or a mixed pair thereof, and wherein said cellulose binding modules or said SpyCatcher domains flanking said silk-like protein sequence are linked to said silk-like protein sequence by a linker sequence, and wherein said linker sequence is selected from the group consisting of: a C-terminal linker of SEQ ID NO:6 and a N-terminal linker of SEQ ID NO:5.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1. Phase separation of silk-like protein into a concentrated phase. The darker liquid at the bottom is silk-like protein phase formed by concentration-induced phase separation.

(2) FIG. 2. Sample collected from the phase separated protein concentrate showing droplets of the concentrated silk protein (light microscopy).

(3) FIG. 3. Cryo-electron micrograph from the phase separated dense protein condensate droplet.

(4) FIG. 4. Pulling of fibers from the phase separated dense protein condensate droplet.

(5) FIG. 5. Scanning electron micrograph of pulled and dried filament from the phase separated dense protein droplet.

(6) FIG. 6. Silk-like protein concentrate forms fibrous assemblies when deformed by pulling forces.

(7) FIG. 7. Schematic drawings of plasmids (A) pPMA51, (B) pSA42, (C) pSA60, (D) pSA16 (E) pEEEt20 and (F) pSAEt210 containing silk like sequences.

(8) FIG. 8. Sample collected from the phase separated protein concentrate showing droplets of the concentrated silk protein (light microscopy).

(9) FIG. 9. Scanning electron micrograph of pulled and dried filament from the phase separated dense protein droplet.

(10) FIG. 10. Silk-like protein concentrate forms fibrous assemblies when deformed by pulling forces.

(11) FIG. 11. Scanning electron micrograph of alignment of the molecules in the fibrous assembly formed by the silk-like molecules.

(12) FIG. 12. Three-dimensional structures of the terminal domains. Left panel; Structure of family three cellulose binding module (CBM) from Clostridium thermocellum (PDB: 1NBC). Right panel; Structure of SpyCatcher domain from Streptococcus pyogenes (PDB: 4MLI).

(13) FIG. 13. Adhesion of different types of materials using the protein concentrate.

(14) FIG. 14. The lap-shear strength of the protein concentrate adhesive for different types of materials.

(15) FIG. 15. Showing the strength of such joints made with protein concentrate adhesive by hanging 4.5 kg of weight from it.

DESCRIPTION OF EMBODIMENTS

(16) The invention involves forming a protein concentrate from a solution of the silk-like proteins after production of the silk-like proteins in the recombinant production host. The concentrate is formed by concentrating a solution of the silk-like proteins without the need for a purification step such as protein precipitation or chromatographic purification. The concentrate is characterized by being a detectable and separate liquid phase, distinct from the aqueous phase from which it was formed.

(17) The present invention thus provides a method for producing a condensed phase of a silk fusion protein, the method comprising the steps of

(18) a) preparing a solution of a silk fusion protein in an aqueous medium, wherein said fusion protein is isolated from a recombinant production host and comprises a silk-like protein sequence and two separate non-silk terminal module sequences flanking said silk-like protein sequence;

(19) b) concentrating said fusion protein in said aqueous medium, until a liquid phase separation occurs;

(20) c) collecting a protein-rich phase of said aqueous medium obtained in step b)

(21) d) repeating steps b) and c) with the protein-rich phase obtained in step c) until a protein concentration of about 20-45% w/v is reached;

(22) e) optionally separating aggregates of the fusion protein from soluble fusion proteins obtained in step d) and removing the aggregates from the solution;

(23) f) concentrating the solution obtained in step d) or e) to the final protein concentration of about 60-80% w/v, wherein the steps a) to f) are performed so that said silk fusion protein is not precipitated and subsequently dissolved to said aqueous medium.

(24) The expression “non-silk terminal module sequences” refers herein to two protein domains flanking said silk-like protein sequence, said two domains having identical or nearly identical (i.e. at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology or sequence identity) amino acid sequences. In an alternative embodiment, said non-silk terminal module sequences flanking silk-like protein sequences have similar three-dimensional structures. Said non-silk terminal module sequences are not present in combination with silk proteins sequences in nature. Suitable terminal module sequences for the silk fusion protein of the present invention preferably have the three-dimensional structure as described in FIG. 12. Said three-dimensional structure comprises consecutive β-strands forming a β-sheet, preferably at least four consecutive β-strands. The length of the amino acid sequence for the terminal module is preferably in the range of 90-250 amino acids, more preferably 98-239 amino acids (see Table 1). Preferably, said protein domains are selected from the group of carbohydrate binding modules (CBMs) such as the cellulose binding module from Clostridium thermocellum comprising the sequence of SEQ ID NO:7. We also disclose terminal module sequences based on the SpyCatcher domain engineered from fibronectin-binding protein FbaB of Streptococcus pyogenes comprising the sequence of SEQ ID NO:14, gamma-crystallin D from Homo sapiens comprising the sequence of SEQ ID NO:20, and tenth type III module of Fibronectin from Homo sapiens comprising the sequence of SEQ ID NO:18. For other preferred embodiments, suitable terminal module peptides for the silk fusion protein are listed in Table 1. In a preferred embodiment, a non-silk terminal module sequence can be paired with another non-silk terminal module sequence having a corresponding three-dimensional structure. For instance, when one of the flanking terminal module sequences in a silk fusion protein is a CBM, the other can be a SpyCatcher domain.

(25) The term “aqueous medium” refers herein to a liquid medium which preferably can be distilled water or a buffer consisting of water and a mixture of a weak acid and its conjugate base.

(26) The term “a silk-like protein sequence” refers herein to amino acid sequences comprising repetitive sequences capable of forming silk fibrillar structures or silk fibers. Preferably, silk-like protein sequence is a spider silk protein sequence or a variant thereof from a spider of order Araneae.

(27) The term “variant” as used herein means amino acid or nucleic acid sequence having high homology to a parent sequence. Preferably, the variant has 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology (i.e. sequence identity) to the parent sequence. Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLASTp and BLASTn 2.0 algorithms, which are described in Altschul et al. (1997) Nucleic Acids Res 25(17):3389-3402.

(28) Preferably, the above method comprises a further step of:

(29) g) preparing silk fusion protein filaments from the concentrate obtained from step f). More preferably, the filaments are prepared in step g) by pulling the filaments from the concentrate by shear force. An example is shown in FIG. 4.

(30) In a preferred embodiment, the method comprises a further initial step of isolating recombinant fusion protein from a host cell expressing said fusion protein. In certain embodiments the invention requires production of recombinant silk-like proteins (e.g. SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 15; SEQ ID NO: 19; SEQ ID NO: 21) in a form where both the amino and carboxy ends of the silk protein have additional non-silk terminal module sequences added (FIG. 7). As discussed above, these non-silk terminal module sequences can be, for example, Cellulose-Binding-Modules (CBMs) (e.g. SEQ ID NO:7), SpyCatcher domains engineered from fibronectin-binding protein FbaB of Streptococcus pyogenes (e.g. SEQ ID NO:14), gamma-crystallin D from Homo sapiens comprising the sequence of SEQ ID NO:20 and tenth type III module of Fibronectin from Homo sapiens comprising the sequence of SEQ ID NO:18, variants thereof, or a mixed pair thereof (for further alternatives see Table 1). The additional protein sequences may also incorporate sequences of amino acids serving as linkers between the non-silk terminal module sequences and the silk sequence (SEQ ID NO: 5; SEQ ID NO: 6). The silk-like part can be repeats of A (SEQ ID NO: 1) and Q (SEQ ID NO: 2) sequences or naturally found sequences such as SEQ ID NO: 3 or SEQ ID NO: 4. Preferably, said spider silk protein repeat sequence comprises 10-50 silk polymer repeats, wherein the repeat sequence consists of repeat A sequence of SEQ ID NO: 1 or a variant thereof combined with repeat Q sequence of SEQ ID NO: 2 or a variant thereof. More preferably, said spider silk protein repeat sequence is (AQ)12. In another preferred embodiment, said spider silk protein repeat sequence is found in ADF3 from Araneus diadematus comprising the sequence of SEQ ID NO:3, the Latrodectus hesperus AcSp1 sequence of SEQ ID NO:4 or a variant thereof. Said linkers can preferably be selected from the group consisting of: a C-terminal linker of SEQ ID NO:6 and a N-terminal linker of SEQ ID NO:5.

(31) In a preferred embodiment, concentration steps b) and f) of the present method are performed by a centrifugal force, dialysis such as ultrafiltration techniques, and/or evaporation. In the Examples below, centrifugal force and evaporation are used in different stages of the method.

(32) The present invention is also providing a silk filament produced by the method of the invention. Preferably, said silk filament is composed of spider silk fusion protein as defined above. More preferably, said silk filament is composed of a spider silk fusion protein comprising 12 silk polymer repeats, wherein the repeat sequence consists of repeat A sequence of SEQ ID NO: 1 combined with repeat Q sequence of SEQ ID NO: 2, and two cellulose binding modules (CBM) from Clostridium thermocellum consisting of the sequence of SEQ ID NO:7 flanking said silk polymer repeats, each module linked to said repeats with a C-terminal linker of SEQ ID NO:6 or a N-terminal linker of SEQ ID NO:5. In an alternative embodiment, said silk filament is composed of spider silk protein repeat sequence ADF3 of SEQ ID NO:3, or the Latrodectus hesperus AcSp1 sequence of SEQ ID NO:4; and two cellulose binding modules (CBM) from Clostridium thermocellum consisting of the sequence of SEQ ID NO:7 flanking said silk protein repeats, each module linked to said repeat sequence ADF3 or the Latrodectus Hesperus AcSp1 sequence with a C-terminal linker of SEQ ID NO:6 or a N-terminal linker of SEQ ID NO:5.

(33) The present invention is also providing a concentrate of spider silk fusion protein produced by the steps a)-f) of the method as defined above and in the claims.

(34) The present invention is further related to a recombinant spider silk fusion protein comprising silk polymer repeats, wherein the repeat sequence consists of repeat A sequence of SEQ ID NO: 1 combined with repeat Q sequence of SEQ ID NO: 2, and two cellulose binding modules (CBM) from Clostridium thermocellum consisting of the sequence of SEQ ID NO:7 flanking said silk polymer repeats, each module linked to said repeats with a C-terminal linker of SEQ ID NO:6 or a N-terminal linker of SEQ ID NO:5. Preferably, the silk polymer repeat sequence is (AQ)12. More preferably, said recombinant spider silk fusion protein comprises the sequence of SEQ ID NO:8.

(35) In an alternative embodiment, said recombinant spider silk fusion protein comprises spider silk protein repeat sequence ADF3 of SEQ ID NO:3, or the Latrodectus Hesperus AcSp1 sequence of SEQ ID NO:4; and two cellulose binding modules (CBM) from Clostridium thermocellum consisting of the sequence of SEQ ID NO:7 flanking said silk protein repeats, each module linked to said repeat sequence ADF3 or the Latrodectus Hesperus AcSp1 sequence with a C-terminal linker of SEQ ID NO:6 or a N-terminal linker of SEQ ID NO:5.

(36) In a further alternative embodiment, said recombinant spider silk fusion protein comprises spider silk protein repeat sequence Araneus diadematus ADF3 of SEQ ID NO:3, and two SpyCatcher domains engineered from fibronectin-binding protein FbaB of Streptococcus pyogenes consisting of the sequence of SEQ ID NO:14 flanking said silk protein repeat sequence, each domain linked to said repeat sequence ADF3 with a C-terminal linker of SEQ ID NO:6 or a N-terminal linker of SEQ ID NO:17.

(37) In a further alternative embodiment, said recombinant spider silk fusion protein comprising spider silk protein repeat sequence Araneus diadematus ADF3 of SEQ ID NO:3, and two tenth type III modules of Fibronectin from Homo sapiens consisting of the sequence of SEQ ID NO:18 flanking said silk protein repeat sequence, each domain linked to said repeat sequence ADF3 with a C-terminal linker of SEQ ID NO:6 or a N-terminal linker of SEQ ID NO:17.

(38) In a further alternative embodiment, said recombinant spider silk fusion protein comprising spider silk protein repeat sequence Araneus diadematus ADF3 of SEQ ID NO:3, and two gamma-crystallin D domains from Homo sapiens consisting of the sequence of SEQ ID NO:20 flanking said silk protein repeat sequence, each domain linked to said repeat sequence ADF3 with a C-terminal linker of SEQ ID NO:6 or a N-terminal linker of SEQ ID NO:17.

(39) A recombinant nucleic acid expressing the fusion protein as defined above and a host cell comprising said nucleic acid are in the scope of the present invention (e.g. SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:16; SEQ ID NO: 22; SEQ ID NO:23).

(40) As defined above as optional step e): the solution can be clarified from cell debris and particulate matter by filtration or sedimentation by centrifugation prior to the formation of the concentrate. This step can be further enhanced by prior heating the solution to above 70 degrees Celsius. It is a distinct advantage of the invention that no precipitation of the silk-like protein is performed. The lack of a precipitation step also makes it unnecessary to involve a step of dissolving the precipitate. The use of dissolving solutions can cause damage to silk proteins and therefore the invention shows an advantage in avoiding the use of these. The omission of a precipitation of the silk-like protein and subsequent dissolving also facilitates processing and scale-up of the process. The lack of a chromatographic purification step reduces cost and makes scale-up of the process easier. The formation of the concentrate occurs as a phase separation event where the concentrate of silk-like protein distinctly forms a fluid phase that is rich in protein (see FIG. 1). This concentrate can be described as a phase separated protein solution, a dope, or also as a protein coacervate. By imaging in a microscope it is evident that sometimes the protein concentrate is visible as droplets in solution (FIGS. 2 and 3). A distinct advantage of the invention is that a high concentration of protein in the condensed phase is formed without other processing steps than a clarification and concentration step. The protein concentration in the concentrate can be further increased by for example evaporation. The protein concentrate has some distinct advantageous properties. From this concentrate it is possible to make fibers of the silk-like protein. The fibers are made by applying an extensional force on the concentrate. The extension of the concentrate leads to the formation of a fiber of silk-like protein as demonstrated in FIG. 4. The formation of fibers from the direct extension of the protein concentrate is advantageous because fibers can be formed without the need for a coagulation bath. The fibers can be formed with the surrounding medium being air, and the extrusion into a liquid is therefore not necessary. Another distinct advantageous of the protein concentrate is that it can be applied to various surfaces and it can act as water-based adhesive.

(41) The adhesive of the present invention can be used by applying to a substrate preferably selected from the group consisting of plastics, glasses, metals, wood, paper, textiles and tissue substrates. That is, it can be used to adhere or fix the substrate. The mode of use follows the general mode of adhesive use, and the typical mode is coating.

(42) Examples of medical or biological applications of the adhesive of the present invention are as follows, but not limited thereto: (1) orthopedic treatments such as treatment of bone, ligament, tendon, meniscus, and muscle, and implant of artificial materials; (2) treatment of perforations, lacerations, and cuts, and ophthalmic attachments such as corneal implants and artificial corneal implants; (3) dental attachments such as holding retainers, bridges, or crowns in place, securing loose teeth, repairing broken teeth, and holding fillers in place; (4) surgical treatments such as attachment of blood vessels, attachment of cellular tissue, artificial material implants, and closure of wounds; and (5) plant attachments such as bonding of transplanted parts and wound healing.

INDUSTRIAL APPLICABILITY

(43) Silk-like proteins can be used in general to form materials such as coatings, fibers, filters, composites, automotive parts, medical materials (wound dressings, drug delivery materials, coatings, cell growth substrates). Advantages are their biocompatibility, biodegradability, the possibility to engineer and modify properties, their mechanical properties, the water-based processing, strength, toughness, and elasticity. The material can also be used for textile and clothing applications.

(44) Adhesives have a very wide applicability in industry, for example in making composite materials, or fixing components of materials together. In a composite material, the adhesive is combined with other components and the adhesive can comprise also a minor part of the composition. In the composite material the adhesive functions as a matrix that binds the components of the material together. Other applications of an adhesive is to fix components of a device together.

(45) Gluing applications include biomedical or medical industry. Adhesives can be used for gluing of tissue, skin, dental applications, wounds, bone, implants, sensors.

(46) Having now generally described the invention, the same will be more readily understood by reference to the following Examples, which is provided by way of illustration and is not intended as limiting.

(47) Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below.

EXAMPLES

Example 1

(48) Protein Production.

(49) Plasmids (see FIG. 7) containing silk-like protein sequences (SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; or SEQ ID NO:16) were transformed into E. coli and grown in Luria Bertani (LB) media (or other bacterial growth media) until an optical density of about 0.5 AU at 600 nm is reached. Protein production was induced by adding Isopropyl β-D-1-thiogalactopyranoside (IPTG) and allowing cells to grow for 12 hours. When autoinduction media such as MAGICMEDIA™ (Thermo Fisher Scientific) was used, no isopropyl β-D-1-thiogalactopyranoside (IPTG) was added MAGICMEDIA™ is an auto induction growth media used with T7-regulated E. coli strains that facilitates protein expression without the addition of IPTG. Cells were broken by sonication. Alternatively, homogenizer such as Avestin Emulsiflex-C3 was used. Also, other cell lysis techniques can be used. Cell debris was removed by centrifugation.

(50) Preparation of Solutions of Proteins.

(51) The clarified supernatant was heated to, for example, 75 degrees Celsius to precipitate material from the supernatant, while the silk-like protein remained in solution.

(52) As a following step, the solution containing protein was subjected to desalting using a desalting chromatography column, or alternatively using ultrafiltration. The solvent of the protein can be changed during the desalting to, for example, water or 5-50 mM Tris buffer containing 0-100 mM NaCl. The concentration of silk-like protein was determined by its optical absorbance at 280 nm.

(53) Forming a Condensed Protein Phase.

(54) A centrifugal concentrator at 25 degrees centigrade was used for concentrating fusion proteins solution from the previous step. During the increase in protein concentration, a phase separation occurred and a protein-rich condensed phase is formed. The protein-rich phase was collected and processed further. The phase separation occurred once the total concentration of protein solution reached around 1% w/v. The protein was then further concentrated in a second concentration step. The collected protein-rich, phase separated solution from the previous step, concentrated further gradually to approximately 10-15% w/v using a centrifugal concentrator at 25 degree Celsius and 845-1500 relative centrifugation force. To determine the concentration of proteins at these concentrations more accurate dry weight measurements were performed.

(55) The increase in concentration can also be achieved by different types of ultrafiltration techniques, by dialysis, or by evaporation.

(56) Third Concentration Step Using the Protein Rich-Phase.

(57) Silk protein at a concentration of 10-15% w/v was further concentrated by evaporation in order to reach concentration of approximately 20-45% w/v.

(58) During the concentration steps, a cleaning step may be necessary: To obtain homogenous and non-flocculating solution, aggregates, and short filaments (nanometer in diameter and couple of micrometer in length which usually form a network), and gel particles (dimensions of around couple of micrometer) were removed from the solution (by centrifugation). Removing aggregates facilitates subsequent fiber pulling or other processing.

(59) Storage Step:

(60) 20-45% w/v is the storage concentration for the dope solution. Samples were rapidly frozen using liquid nitrogen after the third concentration step.

Example 2

(61) Making Fibers from the Protein Concentrate.

(62) A drop of protein solution (at approximately 30%, or 20-45%) as prepared in Example 1 was concentrated further by evaporation to 60-80% and is placed between two tip shaped objects (such as the tips of tweezers).

(63) At around 60-80% w/v protein, a filament could be pulled from the protein solution. An example of fiber pulling is shown in FIG. 4.

Example 3

(64) Making Adhesive from the Protein Concentrate.

(65) A droplet of protein solution (at approximately 30% or 20-50%) as prepared in Example 1 was placed between two materials for instance normal paper and allowed to dry for 5 min until the protein concentrate solidify and glue the paper to each other. An example of protein concentrate used as an adhesive can be seen in FIG. 13.

(66) TABLE-US-00001 TABLE 1 Other suitable peptides for use as non-silk terminal module sequences in a silk fusion protein of the invention. SEQUENCE UNIPROT PDB LENGTH NO PROTEIN HOST ID ID (AA) REFERENCE 1 Green Aequorea P42212 1EMA 239 Ormö, M, Cubitt, A. B., Kallio, K., fluorescence victoria Gross, L. A., Tsien, R. Y., Remington, protein (GFP) S. J. Crystal structure of the Aequorea victoria green fluorescent protein. Science 273, 1392-5 (1996). 2 Enhanced Aequorea C5MKY7 4EUL 239 Arpino, J. A., Rizkallah, P. J., Jones, green victoria D. D. Crystal structure of enhanced fluorescence green fluorescent protein to 1.35 a protein resolution reveals alternative (EGFP) conformations for glu222. Plos One 7, e47132-e47132 (2012). 3 Ubiquitin-like Saccharomyces Q12306 chain 98 Mossessova, E., Lima, C. D. Ulp1- protein SMT3 cerevisiae B in SUMO crystal structure and 1EUV genetic analysis reveal conserved interactions and a regulatory element essential for cell growth in yeast. Mol. Cell 5, 865-76 (2000). 4 Thioredoxin 1 Escherichia P0AA25 2TRX 109 Katti, S. K., LeMaster, D. M., Eklund, coli H. Crystal structure of thioredoxin from Escherichia coli at 1.68 A resolution. J. Mol. Biol. 212, 167- 184. (1990) 5 SnoopCatcher Streptococcus A0A0H2UNT6 2WW8 111 Izore, T., Contreras-Martel, C., El- (residues pneumoniae Mortaji, L., Manzano, C., Terrasse, 749-860 of R., Vernet, T., Di-Guilmi, adhesin A. M., Dessen, A. Structural Basis of RrgA's D4 Host Cell Recognition by the Pilus domain) Adhesin from Streptococcus Pneumoniae. Structure 18, 106-15 (2010). 6 Cohesin Clostridium Q06851 1OHZ 162 Carvalho, A. L., Dias, F. M. V., Prates, (residues thermocellum J. A. M., Ferreira, L. M. A., Gilbert, 181-340 from H. J., Davies, G. J., Romao, Cellulosomal- M. J., Fontes, C. M. G. A. Cellulosome scaffolding Assembly Revealed by the Crystal protein A) Structure of the Cohesin-Dockerin Complex Proc. Natl. Acad. Sci. USA 100, 13809-14 (2003). 7 R2 protein Lama A2KD59 1QD0 128 Spinelli, S., Frenken, L. G., (camelid glama Hermans, P., Verrips, T., Brown, K., antibody) Tegoni, M., Cambillau, C. Camelid heavy-chain variable domains provide efficient combining sites to haptens. Biochemistry 39, 1217-22 (2000). 8 Tumor Homo P29965 3LKJ 141 Silvian, L. F., Friedman, necrosis sapiens J. E., Strauch, K., Cachero, factor T. G., Day, E. S., Qian, cytokine F., Cunningham, B., Fung, A., Sun, CD40 ligand L., Su, L., Zheng, Z., Kumaravel, G., Whitty, A. Cunningham et al. Small molecule inhibition of the TNF family cytokine CD40 ligand through a subunit fracture mechanism. ACS chemical biology 6, 636-647. (2011): 9 Tumor Mus Q9D777 Chain 140 Gordon, N. C., Lien, S., Johnson, necrosis musculus Ain J., Wallweber, H. J., Tran, factor 3K48 T., Currell, B., Mathieu, M., Quan, C., Starovasnik, M. A., Hymowitz, S. G., Kelley, R. F. Multiple novel classes of APRIL-specific receptor- blocking peptides isolated by phage display. J. Mol. Biol. 396, 166-177. (2010). 10 B-cell Homo Q9Y275 4V46 148 Kim, H. M., Yu, K. S., Lee, M. E., Shin, activating sapiens D. R., Kim, Y. S., Paik, S. G., Yoo, factor (BAFF) O. J., Lee, H., Lee, J.-O. Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation Nat. Struct. Biol. 10, 342-348 (2003).

REFERENCES

(67) 1. Ebrahimi, D. et al. Silk-Its Mysteries, How It Is Made, and How It Is Used. ACS Biomater. Sci. Eng. 1, 864-876 (2015). 2. Nudelman, F. et al. Forming nacreous layer of the shells of the bivalves Atrina rigida and Pinctada margaritifera: An environmental- and cryo-scanning electron microscopy study. J. Struct. Biol. 162, 290-300 (2008). 3. Rising, A. & Johansson, J. Toward spinning artificial spider silk. Nat. Chem. Biol. 11, 309-315 (2015). 4. Green, M. & Sambrook, J. Molecular cloning. A laboratory manual. Zool. Res. (Cold Spring Harbor Laboratory Press, 2012). doi:10.3724/SP.J.1141.2012.01075 5. U.S. Pat. No. 7,951,908B2. 6. Teule, F. et al. Combining flagelliform and dragline spider silk motifs to produce tunable synthetic biopolymer fibers. Biopolymers 97, 418-431 (2012). 7. Adrianos, S. L. et al. Nephila clavipes flagelliform silk-like GGX motifs contribute to extensibility and spacer motifs contribute to strength in synthetic spider silk fibers. Biomacromolecules 14, 1751-1760 (2013). 8. Albertson, A. E., Teule, F., Weber, W., Yarger, J. L. & Lewis, R. V. Effects of different post-spin stretching conditions on the mechanical properties of synthetic spider silk fibers. J. Mech. Behav. Biomed. Mater. 29, 225-234 (2014). 9. Xia, X.-X. et al. Native-sized recombinant spider silk protein produced in metabolically engineered Escherichia coli results in a strong fiber. Proc. Natl. Acad. Sci. U.S.A. 107, 14059-63 (2010). 10. Gnesa, E. et al. Conserved C-terminal domain of spider tubuliform spidroin 1 contributes to extensibility in synthetic fibers. Biomacromolecules 13, 304-312 (2012). 11. Lin, S. et al. Predictive modelling-based design and experiments for synthesis and spinning of bioinspired silk fibres. Nat. Commun. 6, 1-12 (2015). 12. Heidebrecht, A. et al. Biomimetic Fibers Made of Recombinant Spidroins with the Same Toughness as Natural Spider Silk. Adv. Mater. 27, 2189-2194 (2015). 13. Téule, F. et al. A protocol for the production of recombinant spider silk-like proteins for artificial fiber spinning. Nat. Protoc. 4, 341-55 (2009). 14. Rammensee, S., Slotta, U., Scheibel, T. & Bausch, A. R. Assembly mechanism of recombinant spider silk proteins. Proc. Natl. Acad. Sci. U.S.A. 105, 6590-6595 (2008). 15. Kinahan, M. E et al. Tunable Silk: Using Microfluidics to Fabricate Silk Fibers with Controllable Properties. Biomacromolecules 12, 1504-1511 (2011). 16. Wong Po Foo, C. et al. Novel nanocomposites from spider silk-silica fusion (chimeric) proteins. Proc. Natl. Acad. Sci. U.S.A. 103, 9428-33 (2006). 17. Lang, G., Jokisch, S. & Scheibel, T. Air filter devices including nonwoven meshes of electrospun recombinant spider silk proteins. J. Vis. Exp. 4, e50492 (2013). 18. Hedhammar, M. et al. Structural Properties of Recombinant Nonrepetitive and Repetitive Parts of Major Ampullate Spidroin 1 from Euprosthenops australis: Implications for Fiber Formation †. Biochemistry 47, 3407-3417 (2008). 19. Tremblay, M.-L. et al. Spider wrapping silk fibre architecture arising from its modular soluble protein precursor. Sci. Rep. 5, 11502 (2015). 20. U.S. Pat. No. 8,173,772B2.